

**PRESS RELEASE**

**WILEX subsidiary Heidelberg Pharma receives research grant from the European Union**

- **Heidelberg Pharma is part of the European Training Network MAGICBULLET consortium for the development of new chemistry-driven concepts for anti-tumour therapies**

**Munich, Germany, 25 February 2015** – WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) today announced that its subsidiary Heidelberg Pharma has been awarded a research grant from the European Union as part of the European Training Network (ETN) MAGICBULLET. The European Union supports promising research projects within the Horizon 2020 Framework Programme for Research and Innovation and has granted ETN MAGICBULLET a total of EUR 3.75 million for years 2015-2018 for the development of new chemistry-driven concepts for anti-tumour therapies.

Heidelberg Pharma is part of the ETN MAGICBULLET consortium which consists of seven academic research groups from Germany, Italy, Hungary and Finland, and two pharmaceutical companies (Heidelberg Pharma, Germany and Exiris, Italy). The aim of the consortium is to develop and validate an array of new peptide-drug conjugates combining tumour-specific peptides with potent cytotoxic drugs. Heidelberg Pharma's task is to identify, modify and validate tumour-specific peptide-drug conjugates based on its expertise in linker technology as well as to investigate the biological activity in vitro and in vivo.

Dr Jan Schmidt-Brand, CEO/CFO of WILEX AG and Managing Director of Heidelberg Pharma GmbH, commented: "We are pleased that MAGICBULLET was selected for the HORIZON 2020 programme and we look forward to an intensive and fruitful collaboration with our MAGICBULLET partners. Peptide-drug conjugates are promising new concepts for the therapy of different tumour types."

**About Peptide-Drug Conjugates**

Currently used anti-tumour drugs are highly cytotoxic and therapies often associated with severe side effects. Chemical compounds that specifically recognize molecular structures selectively present on tumour cells would be advantageous to target the delivery of a drug to a tumour cell and specifically eliminate these cells. Peptide-drug conjugates can easily penetrate tissues, and can be simply prepared in a homogenous form and large quantity with straightforward and well-defined conjugation chemistry.

**About ETN MAGICBULLET**

The ETN will develop and validate an array of new peptide-drug conjugates combining tumour-specific peptides with potent cytotoxic drugs. The consortium consists of seven academic research groups from Germany, Italy, Hungary and Finland, and two pharmaceutical companies from Germany and Italy.

More information on the project is available at [www.uni-bielefeld.de/chemie/oc3sewald/magicbullet](http://www.uni-bielefeld.de/chemie/oc3sewald/magicbullet).

**About WILEX and Heidelberg Pharma**

WILEX AG is a biopharmaceutical company which has a ready for partnering portfolio of antibody-based diagnostic and therapeutic Phase III product candidates for the detection and targeted treatment of clear cell renal cell carcinoma. Research and development focus on the operations of its subsidiary Heidelberg Pharma GmbH in Ladenburg, which primarily advances the development of the innovative platform technology for antibody drug conjugates (ADC technology) and provides pre-clinical drug discovery and development services. WILEX is listed at the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at <http://www.wilex.com/>.

**Contact**

WILEX AG

Sylvia Wimmer  
Corporate Communications  
Tel.: +49 (0)89-41 31 38-29  
Email: [investors\[at\]wilex.com](mailto:investors[at]wilex.com)  
Grillparzerstr. 10, 81675 Munich, Germany

**IR/PR support**

MC Services AG

Katja Arnold (CIRO)  
Executive Director  
Tel.: +49-89-210 228-40  
Email: [katja.arnold\[at\]mc-services.eu](mailto:katja.arnold[at]mc-services.eu)

**Business Development**

Heidelberg Pharma GmbH

Dr Marcel Linssen  
CBO, Executive Vice President  
Tel.: +49-(0) 6203 1009-40  
Email: [m.linssen\[at\]hdpharma.com](mailto:m.linssen[at]hdpharma.com)

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.